Best Biotech Stocks to Buy Now (2024)Top biotech stocks in 2024 ranked by overall Zen Score. See the best biotech stocks to buy now, according to analyst forecasts for the biotechnology industry.
Industry: Biotechnology
| Ticker | Company | Country | Market Cap | Shares | Institutional % | Insider % | Net Insider (L12M) | Net Insider (L3M) |
|---|---|---|---|---|---|---|---|---|
| PULM | PULMATRIX INC | United States | $7.16M | 3,652,285 | 4.28% | 95.72% | ||
| OCUL | OCULAR THERAPEUTIX INC | United States | $917.03M | 148,627,439 | 49.43% | 21.84% | Net Buying | Net Buying |
| BYSI | BEYONDSPRING INC | United States | $87.82M | 39,029,163 | 14.01% | 0.00% | ||
| PHAR | PHARMING GROUP NV | Netherlands | $671.07M | 671,073,243 | 0.00% | 0.00% | ||
| URGN | UROGEN PHARMA LTD | Israel | $487.95M | 34,122,087 | 62.74% | 29.32% | Net Buying | Net Selling |
| RXRX | RECURSION PHARMACEUTICALS INC | United States | $2.07B | 234,653,272 | 75.32% | 24.68% | Net Selling | Net Selling |
| MRVI | MARAVAI LIFESCIENCES HOLDINGS INC | United States | $2.26B | 251,399,871 | 35.06% | 64.94% | Net Selling | Net Selling |
| INVA | INNOVIVA INC | United States | $961.06M | 63,227,333 | 58.68% | 41.32% | Net Buying | Net Buying |
| SWTX | SPRINGWORKS THERAPEUTICS INC | United States | $3.34B | 74,086,425 | 64.08% | 35.92% | Net Selling | Net Selling |
| IMRN | IMMURON LTD | Australia | $14.35M | 227,798,346 | 0.00% | 0.00% | ||
| HOWL | WEREWOLF THERAPEUTICS INC | United States | $263.77M | 43,455,367 | 48.08% | 51.92% | ||
| HOOK | HOOKIPA PHARMA INC | United States | $92.02M | 98,950,107 | 35.22% | 26.83% | Net Buying | |
| AADI | AADI BIOSCIENCE INC | United States | $52.05M | 24,554,205 | 26.93% | 73.07% | Net Selling | Net Selling |
| STOK | STOKE THERAPEUTICS INC | United States | $556.57M | 46,303,743 | 40.29% | 59.71% | Net Selling | Net Selling |
| CVAC | CUREVAC NV | Germany | $701.08M | 223,988,675 | 9.83% | 0.00% | ||
| SILO | SILO PHARMA INC | United States | $5.26M | 2,843,634 | 5.65% | 6.35% | Net Buying | Net Buying |
| TARS | TARSUS PHARMACEUTICALS INC | United States | $1.26B | 34,218,886 | 66.40% | 33.60% | Net Selling | Net Selling |
| CLLS | CELLECTIS SA | France | $214.54M | 71,751,201 | 13.68% | 0.00% | ||
| RPTX | REPARE THERAPEUTICS INC | Canada | $145.53M | 42,182,177 | 61.13% | 38.87% | Net Buying | Net Selling |
| CRVO | CERVOMED INC | United States | $148.46M | 6,170,479 | 0.47% | 99.53% | ||
| TCRT | ALAUNOS THERAPEUTICS INC | United States | $20.82M | 16,012,479 | 53.36% | 46.64% | Net Selling | |
| CANF | CAN-FITE BIOPHARMA LTD | Israel | $8.53M | 1,359,837,393 | 0.02% | 0.00% | ||
| IPHA | INNATE PHARMA SA | France | $204.75M | 80,453,282 | 0.16% | 0.00% | ||
| BRTX | BIORESTORATIVE THERAPIES INC | United States | $9.24M | 6,769,919 | 0.28% | 99.72% | Net Buying | Net Buying |
| BLRX | BIOLINERX LTD | Israel | $49.51M | 1,086,589,165 | 0.10% | 0.00% | ||
| PSTX | POSEIDA THERAPEUTICS INC | United States | $276.92M | 96,489,127 | 46.85% | 40.59% | Net Selling | Net Selling |
| CRMD | CORMEDIX INC | United States | $321.09M | 54,981,102 | 34.05% | 10.98% | Net Buying | Net Buying |
| KRON | KRONOS BIO INC | United States | $61.30M | 60,095,013 | 44.51% | 42.51% | Net Buying | Net Selling |
| ANNX | ANNEXON INC | United States | $439.32M | 90,025,573 | 76.31% | 23.69% | Net Buying | Net Selling |
| BDTX | BLACK DIAMOND THERAPEUTICS INC | United States | $359.96M | 51,717,849 | 60.10% | 39.90% | Net Buying | Net Buying |
| ACST | ACASTI PHARMA INC | Canada | $27.82M | 9,399,404 | 6.08% | 64.72% | Net Buying | |
| KTTA | PASITHEA THERAPEUTICS CORP | United States | $7.21M | 1,042,415 | 2.22% | 97.78% | Net Buying | |
| VIR | VIR BIOTECHNOLOGY INC | United States | $1.41B | 136,058,680 | 62.26% | 37.74% | Net Selling | Net Selling |
| SNDX | SYNDAX PHARMACEUTICALS INC | United States | $1.87B | 84,965,486 | 91.35% | 8.65% | Net Buying | |
| BCYC | BICYCLE THERAPEUTICS PLC | United Kingdom | $1.05B | 42,779,030 | 54.60% | 45.40% | Net Selling | Net Selling |
| IPSC | CENTURY THERAPEUTICS INC | United States | $196.40M | 64,817,863 | 27.27% | 59.23% | Net Selling | Net Selling |
| EXAI | EXSCIENTIA PLC | United Kingdom | $587.03M | 125,702,396 | 24.77% | 0.00% | ||
| XBIT | XBIOTECH INC | United States | $258.53M | 30,450,881 | 11.32% | 45.18% | ||
| ANAB | ANAPTYSBIO INC | United States | $711.36M | 26,763,081 | 41.94% | 58.06% | Net Selling | Net Selling |
| VCEL | VERICEL CORP | United States | $2.31B | 48,290,164 | 91.15% | 8.85% | Net Selling | Net Selling |
| CLSD | CLEARSIDE BIOMEDICAL INC | United States | $97.88M | 74,721,139 | 10.37% | 36.40% | Net Buying | Net Buying |
| ACAD | ACADIA PHARMACEUTICALS INC | United States | $2.81B | 164,771,521 | 71.22% | 28.78% | Net Buying | Net Selling |
| ZNTL | ZENTALIS PHARMACEUTICALS INC | United States | $830.94M | 70,960,165 | 73.56% | 26.44% | Net Buying | Net Selling |
| ABEO | ABEONA THERAPEUTICS INC | United States | $125.83M | 27,355,037 | 25.74% | 74.26% | Net Buying | Net Buying |
| PASG | PASSAGE BIO INC | United States | $72.83M | 55,598,796 | 43.60% | 56.40% | Net Buying | Net Selling |
| ACET | ADICET BIO INC | United States | $119.12M | 82,153,984 | 40.62% | 19.50% | Net Buying | |
| EQ | EQUILLIUM INC | United States | $58.88M | 35,254,752 | 21.71% | 40.89% | Net Buying | |
| CGON | CG ONCOLOGY INC | United States | $2.42B | 66,636,252 | 0.00% | 16.44% | Net Buying | |
| CNTA | CENTESSA PHARMACEUTICALS PLC | United Kingdom | $949.90M | 100,305,850 | 71.06% | 14.21% | Net Selling | Net Selling |
| AVIR | ATEA PHARMACEUTICALS INC | United States | $333.29M | 84,164,545 | 65.45% | 25.19% | Net Selling | |
| NRIX | NURIX THERAPEUTICS INC | United States | $628.15M | 49,150,794 | 84.43% | 15.57% | Net Selling | Net Selling |
| PMVP | PMV PHARMACEUTICALS INC | United States | $102.37M | 51,443,488 | 62.78% | 37.22% | Net Buying | |
| VRCA | VERRICA PHARMACEUTICALS INC | United States | $307.96M | 42,418,553 | 41.10% | 58.90% | Net Buying | |
| VXRT | VAXART INC | United States | $126.75M | 173,861,684 | 9.16% | 69.71% | Net Selling | Net Selling |
| CBUS | CIBUS INC | United States | $411.69M | 24,132,009 | 14.04% | 85.96% | Net Buying | |
| LPTX | LEAP THERAPEUTICS INC | United States | $81.66M | 25,600,137 | 12.25% | 87.75% | ||
| LVTX | LAVA THERAPEUTICS NV | Netherlands | $79.66M | 26,289,087 | 22.20% | 0.00% | ||
| DYAI | DYADIC INTERNATIONAL INC | United States | $41.43M | 28,974,105 | 7.98% | 92.02% | ||
| CGEM | CULLINAN THERAPEUTICS INC | United States | $1.22B | 43,065,645 | 48.26% | 51.74% | Net Selling | |
| KURA | KURA ONCOLOGY INC | United States | $1.57B | 76,180,620 | 90.77% | 9.23% | Net Buying | |
| SABS | SAB BIOTHERAPEUTICS INC | United States | $37.18M | 9,225,494 | 40.51% | 59.49% | Net Buying | |
| PCSA | PROCESSA PHARMACEUTICALS INC | United States | $6.20M | 2,855,981 | 23.32% | 76.68% | Net Buying | Net Buying |
| ARTL | ARTELO BIOSCIENCES INC | United States | $4.36M | 3,227,700 | 0.76% | 25.83% | ||
| OMGA | OMEGA THERAPEUTICS INC | United States | $142.30M | 55,154,985 | 57.75% | 42.25% | Net Selling | |
| TARA | PROTARA THERAPEUTICS INC | United States | $59.92M | 20,589,976 | 11.95% | 88.05% | Net Selling | |
| DOMH | DOMINARI HOLDINGS INC | United States | $13.65M | 5,934,917 | 7.25% | 92.75% | Net Buying | Net Buying |
| ATHA | ATHIRA PHARMA INC | United States | $75.12M | 38,326,652 | 57.11% | 31.41% | Net Buying | |
| NKTX | NKARTA INC | United States | $365.68M | 49,416,186 | 53.86% | 46.14% | Net Buying | Net Buying |
| NBTX | NANOBIOTIX SA | France | $287.51M | 47,133,328 | 19.67% | 0.00% | ||
| VRAX | VIRAX BIOLABS GROUP LTD | United Kingdom | $1.11M | 1,811,540 | 7.37% | 0.00% | ||
| PCVX | VAXCYTE INC | United States | $7.15B | 108,407,730 | 83.78% | 16.22% | Net Selling | Net Buying |
| LGND | LIGAND PHARMACEUTICALS INC | United States | $1.31B | 17,705,287 | 14.99% | 85.01% | Net Buying | Net Buying |
| ADMA | ADMA BIOLOGICS INC | United States | $1.55B | 228,220,236 | 74.12% | 24.57% | Net Selling | Net Selling |
| XENE | XENON PHARMACEUTICALS INC | Canada | $3.30B | 75,432,482 | 95.45% | 3.29% | Net Selling | Net Selling |
| BNTC | BENITEC BIOPHARMA INC | Australia | $23.20M | 2,592,434 | 46.20% | 37.31% | ||
| MORF | MORPHIC HOLDING INC | United States | $1.50B | 50,093,588 | 64.32% | 35.68% | Net Selling | Net Buying |
| LTRN | LANTERN PHARMA INC | United States | $66.06M | 10,741,324 | 10.76% | 66.23% | Net Selling | Net Selling |
| LENZ | LENZ THERAPEUTICS INC | United States | $136.94M | 8,319,561 | 49.99% | 50.01% | Net Buying | Net Buying |
| PRLD | PRELUDE THERAPEUTICS INC | United States | $211.99M | 54,920,594 | 52.43% | 47.57% | Net Buying | Net Selling |
| NXTC | NEXTCURE INC | United States | $42.80M | 27,973,289 | 47.70% | 50.08% | ||
| STRO | SUTRO BIOPHARMA INC | United States | $239.15M | 62,441,963 | 78.85% | 21.15% | Net Selling | Net Selling |
| ORIC | ORIC PHARMACEUTICALS INC | United States | $654.22M | 67,375,847 | 70.31% | 29.69% | Net Selling | Net Selling |
| GDTC | CYTOMED THERAPEUTICS LTD | Singapore | $23.71M | 11,540,000 | 0.04% | 57.45% | ||
| BCRX | BIOCRYST PHARMACEUTICALS INC | United States | $917.37M | 206,149,929 | 83.05% | 16.95% | Net Selling | Net Selling |
| TYRA | TYRA BIOSCIENCES INC | United States | $937.50M | 52,521,050 | 59.50% | 40.50% | Net Buying | Net Selling |
| IPA | IMMUNOPRECISE ANTIBODIES LTD | Canada | $33.68M | 26,315,260 | 6.56% | 0.00% | ||
| CMPX | COMPASS THERAPEUTICS INC | United States | $233.90M | 137,589,171 | 62.59% | 12.24% | Net Buying | Net Selling |
| ERAS | ERASCA INC | United States | $324.20M | 151,494,161 | 44.64% | 55.36% | Net Buying | |
| GPCR | STRUCTURE THERAPEUTICS INC | United States | $1.83B | 139,794,124 | 30.46% | 15.04% | ||
| QNCX | QUINCE THERAPEUTICS INC | United States | $42.57M | 43,215,233 | 15.43% | 84.57% | Net Buying | |
| AURA | AURA BIOSCIENCES INC | United States | $390.59M | 49,504,405 | 74.74% | 17.47% | Net Buying | |
| ALDX | ALDEYRA THERAPEUTICS INC | United States | $247.16M | 59,414,489 | 59.11% | 33.90% | Net Selling | Net Buying |
| EPIX | ESSA PHARMA INC | Canada | $304.36M | 44,238,147 | 73.10% | 26.90% | Net Buying | Net Buying |
| ENTX | ENTERA BIO LTD | Israel | $76.64M | 35,481,341 | 11.45% | 3.79% | Net Buying | |
| SNPX | SYNAPTOGENIX INC | United States | $5.52M | 1,085,334 | 79.75% | 20.25% | ||
| WVE | WAVE LIFE SCIENCES LTD | Singapore | $750.82M | 122,284,139 | 61.18% | 38.82% | Net Buying | Net Selling |
| ABOS | ACUMEN PHARMACEUTICALS INC | United States | $209.68M | 60,079,778 | 63.98% | 16.58% | Net Buying | |
| CDTX | CIDARA THERAPEUTICS INC | United States | $57.07M | 4,561,751 | 61.60% | 38.40% | Net Selling | Net Selling |
| LRMR | LARIMAR THERAPEUTICS INC | United States | $495.41M | 63,800,017 | 42.05% | 57.95% | Net Buying | Net Buying |
| VRNA | VERONA PHARMA PLC | United Kingdom | $1.27B | 646,524,958 | 10.44% | 55.89% | Net Selling | Net Selling |
Biotech Stocks FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.